Home » Authors » Karen Carey

Articles by Karen Carey

TargeGen's Series B Brings In $30M For AMI, Cancer Programs

Jan. 16, 2004

Enanta Raises $12M To Further Macrolide Respiratory Program

Jan. 15, 2004

BioStratum Could Receive $80M Per Antibody In Novo Cancer Deal

Jan. 14, 2004

Acumen, Merck Sign Alzheimer's Disease Pact With $96M Potential

Jan. 14, 2004

Concurrent Raises $15M, Partners With Intel On 'Machine Learning'

Jan. 13, 2004

$19M Private Placement Ranks As Cortex's 'Biggest Financing'

Jan. 12, 2004

ImmunoGen Moving Forward Alone With Cancer Products

Jan. 9, 2004

Forbes Medi-Tech Private Placement Raises $10.75M

Jan. 8, 2004

Diversa Licenses Technologies Through XOMA, Cellectis Deals

Jan. 7, 2004

Repligen's Secretin Fails Autism Phase III; Subgroup Has Promise

Jan. 6, 2004

The new year greeted Repligen Corp. with disappointing data from its Phase III trial of synthetic human secretin in autism. (BioWorld Today)

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...